Bejing Chaoyang Hospital provided medical service support as a designated hospital for the Beijing 2008 Olympic Games. In the course, the hospital is benefited in terms of its management system building, guarantee of medical service quality, effective connection within the service system,real-time improvement of medical service quality, comprehensive information management and development of the emergency treatment system. These experiences are being converted into part of the permanent mechanism, rendering profound influence on medical service support for large-scale activities in the future.

Objective:To investigate the effect of cisplatin on the expression of programmed death factor ligand 1 (PD-L1) in SGC-7901 cells of gastric cancer and the regulation of lymphocyte on the proliferation of gastric cancer cell.Methods:Flow cytometry was used to detect the expression of PD-L1 on the surface of SGC-7901 cells. After cisplatin pretreatment, SGC-7901 cells were co-incubated with the activated lymphocytes. In group B, SGC-7901 + lymphocytes were not treated with cisplatin. Cisplatin treated SGC-7901 + lymphocytes were in group C. The apoptosis of CD 4+ and CD 8+ T cells in each group was detected by flow cytometry. The dissolution rate of SGC-7901 cells was calculated by ADCC method. Results:MTT results showed that cisplatin inhibited the proliferation effect of SGC-7901 cells in a concentration-dependent manner after 48 h′ cisplatin treatment ( F = 128.35, P < 0.05). After SGC-7901 cells were treated with cisplatin for 0, 0.5, 1.0, 2.0, 4.0 mg/L, the expression of PD-L1 on the cell surface was up-regulated, and after cisplatin treatment for more than 1.0 mg/L, the expression began to decline ( F = 477.79, P<0.05). After cisplatin treatment, SGC-7901 cells were co-incubated with lymphocytes, which increased the apoptosis rate of lymphocytes ( F = 524.98 and 122.47, P<0.05). When human peripheral blood mononuclear cells and target SGC-7901 cells were incubated, cisplatin could mediate the killing activity of human peripheral blood mononuclear cells on human SGC-7901 cells, (ADCC effect), and cisplatin could weaken the killing activity ( t = 15.961, P < 0.05). Conclusions:Cisplatin may inhibit the killing activity of human peripheral mononuclear cells to SGC-7901 cells of gastric cancer and weaken the death of gastric cancer cells by inducing the expression of PD-L1 in SGC-7901 cells.

Background: and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods: This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation,treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results: Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.

Background: and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods: This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation,treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results: Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.